ADP-A2M4 (MAGE-A4)

Anderson VE, Weber AM, Wiedermann GE, Pachnio A, Dauleh S, Ahmed T, Docta RY, Quattrini A, Pope G, Quinn L, Ashton TM, Tunbridge HM, Sanderson JP, Gerry AB. Enhanced activity of second-generation MAGE-A4 SPEAR T-cells through co-expression of a CD8a homodimer. In: AACR Conference Proceedings; March 29-April 3, 2019; Atlanta, GA. Abstract 2313.

Hong DS, Butler MO, Johnson M, Olszanski AJ, Norry E, Van Winkle E, Chagin KD, Amado RG. 1156P Initial safety assessment of MAGE-A4 SPEAR T-cells. Annals of Oncology 2018;29(suppl 8):mdy288.029.

Senra J, Villalobos P, Mino B, Solis L, Behrens C, Sanderson JP, Saini M, Gerry AB, Pumphrey NJ, Maroto M, Sepesi B, Hwu P, Hong DS, Mittendorf EA, Blumenschein GS, Wistuba II, Binder-Scholl G, Amado R. Affinity-enhanced T-cell receptor (TCR) for adoptive T-cell therapy targeting MAGE-A4. In: AACR Conference Proceedings; April 14-18, 2018; Chicago, IL. Abstract 2562.

Hong DS, Johnson M, Olszanski AJ, Bulter M, Erickson-Miller C, Iyengar M, Trivedi T, Chagin K, Amado R. Study design: phase 1 dose escalation, multi-tumor study to assess safety, tolerability and antitumor activity of genetically engineered MAGE-A4 SPEAR T-cells in HLA-A2+ subjects with MAGE-A4+ tumors.  In: 32^nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two; November 8-12, 2017; National Harbor, MD, Journal for the ImmunoTherapy of Cancer 2017;5(Suppl2):P247.

Gerry AB, Sanderson JP, Howe K, Docta RY, Gao Q, Bagg E, Tribble N, Maroto M. Preclinical evaluation of an optimal-affinity MAGE-A4 T cell receptor for adoptive T cell therapy.  In: 31^st Annual Meeting and Associated Programs of the Society for Immuotherapy of Cancer (SITC 2016): Part One; November 9-13, 2016; National Harbor, MD, Journal for the ImmunoTherapy of Cancer 2016;4(Suppl 1):P3

ADP-A2M10 (MAGE-A10)

Border EC, Sanderson JP, Weissensteiner T, Gerry AB, Pumphrey NJ. Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate. OncoImmunology 2018:1-12.

Lam VK, Hong DS, Heymach JV, Blumenschein G, Butler MO, Johnson M, Creelan B, Gainor JF, Govindan R, Mudad R, Neal J, Brophy F, Fang F, Hyland N, Holdich T, Ma Y, Trivedi T, Norry E, Amado RG. LBA38 Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Annals of Oncology 2018;29 (suppl 8):mdy424.048.

Lam V, Hong DS, Heymach J, Blumenschein GR, Creelan B, Bradbury P, Butler M, Gainor J, Govindan R, Johnson M, Mudad R, Sullivan RJ, Brophy F, Hyland N, Chagin K, Holdich T, Norry E, Amado R. Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials. Journal of Clinical Oncology 2018;36(Suppl 15):3056.

Border E, Sanderson JP, Weissensteiner T, Hyland N, Holdich T, Brophy F, Amado R, Gerry A, Pumphrey N. Selection of affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10. In: AACR Conference Proceedings; April 14-18, 2018; Chicago, IL. Abstract 2564.

Hong DS, Butler M, Sullivan RJ, Erickson-Miller C, Trivedi T, Chagin K, Pandite L, Amado R. A phase I single arm, open label clinical trial evaluating safety of MAGE-A10c796T in subjects with advanced or metastatic head and neck, melanoma or urothelial tumors (NCT02989064). Journal of Clinical Oncology 2017;35(Suppl 15):TPS3098.

Creelan B, Gainor J, Govindan R, Hardy NM, Heymach J, Mudad R, Reckamp K, Bardwell W, Holdich T, Pandite L, Amado R. Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577). Journal of Clinical Oncology 2017;35(Suppl 15):TPS3096.  

Gerry AB, Sanderson JP, Saini M, Tavano B, Docta RY, Pumphrey N, Border EC, Bennett AD, Jakobsen B. Preclinical safety testing of an optimized enhanced-affinity MAGE-A10-specific T cell receptor for adoptive T cell therapy.  In: 30^th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015); November 4-8, 2015; National Harbor, MD, Journal for the ImmunoTherapy of Cancer 2015;3(Suppl 2):P15.

ADP-A2AFP (AFP)

Goyal L, Frigault M, Meyer T, Feun LG, Bruix J, El-Hkoueiry A, Hausner P, Sangro B, Pierce TT, Norry E, Ranganathan S, Amado RG, Finn RS. Initial safety of AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma. In: AACR Conference Proceedings; March 29-April 3, 2019; Atlanta, GA. Abstract 3183.

Docta RY, Ferronha T, Sanderson JP, Weissensteiner T, Pope GR, Bennett AD, Pumphrey NJ, Ferjentsik Z, Quinn LL, Wiedermann GE, Anderson VE, Saini M, Maroto M, Norry E, Gerry AB. Tuning T cell receptor affinity to optimize clinical risk‐benefit when targeting α‐fetoprotein‐positive liver cancer. Hepatology 2019; doi:10.1002/hep.30477.

Gerry AB, Sanderson JP, Maroto M, Ferronha T, Ranganathan S, Norry E, Pandite L, Amado R, Jakobsen B. Targeting alpha fetoprotein with TCR engineered T cells in HCC. Journal of Clinical Oncology 2016;34(Suppl 15):3051.

Finn RS, Norry E, Ranganathan S, Gerry A, Maroto M, Pandite L, Amado R. Phase I study to evaluate safety and anti-tumor activity of autologous T cells with alpha-feto protein (AFPc332T) receptor in patients with advanced hepatocellular carcinoma (HCC).  Paper presented at: 10th ILCA Annual Conference; September 9-11, 2016; Vancouver, Canada.

Research and Reviews

Carpenter L, Barker L, Sidaway A, Yang C-T, Koerner E, Bardsley K, McEwen-Smith R, Gueguen C, Tipping A, Spinner W, Hamilton G, Wong R, Brewer J. Differentiating T-cells from hiPSCs to create off-the-shelf SPEAR T-cells. In: 2019 ASGCT Abstract Book; April 29-May 2, 2019;  Washington, D.C.  Abstract 990.

Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Therapy 2018;25:175-191.

Tan MP, Dolton GM, Gerry AB, Brewer JE, Bennett AD, Pumphrey NJ, Jakobsen BK, Sewell AK. Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells. Clinical & Experimental Immunology 2017;187(1):124-137.  

Bossi G, Gerry AB, Paston SJ, Sutton DH, Hassan NJ, Jakobsen BK. Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells. Oncoimmunology 2013;2(11):e26840.   

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013;122(6):863-871.

Smethurst D. A pharmacologic perspective on newly emerging T-cell manipulation technologies. British Journal of Clinical Pharmacology 2013;76(2):173-187.

NY-ESO-1

Stadtmauer EA, Faitg TH, Lowther DE, Badros AZ, Chagin K, Dengel K, Iyengar M, Melchiori L, Navenot J-M, Norry E, Trivedi T, Wang R, Binder GK, Amado R, Rapoport AP. Long‐term safety and activity of NY-ESO‐1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Advances 2019;3:2022-2034.

D'Angelo SP, Melchiori L, Merchant MS, Bernstein DB, Glod J, Kaplan RN, Grupp SA, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite LN, Amado R, Mackall CL. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1c259T cells in synovial sarcoma. Cancer Discovery 2018;8(8):944-957.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine 2015;21(8):914-921.